US FDA’s Real-Time Oncology Review Program Is No Guarantee For Early Approval
Executive Summary
Early approvals may not be feasible for all submissions due to specific issues with an application or overall workload considerations, FDA says in a new draft guidance on the RTOR program; agency recommends bundling components of an RTOR application in a maximum of three partial submissions and a final submission.
You may also be interested in...
Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead
Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO Robert Coleman tells Scrip.
US FDA’s RTOR Program Produces Approvals About One Month Sooner Than Priority Review Goal
Novel agents approved under Real-Time Oncology Review posted a median time to approval of seven months, our Pink Sheet RTOR infographic shows, while other RTOR applications had a median 4.5 month approval time.
Slow Down To Speed Up: US FDA Presses Cases For Dose Optimization
The US FDA is urging drug companies to abandon traditional approaches to oncology dosing even if it means slowing down early studies. The trade-off should be faster development times overall, FDA says – but sponsors still seem very wary.